News

Archives

Axxam SpA is a member of the PHAGO Consortium

Axxam SpA is a member of the PHAGO Consortium Milan (Italy) - January, 11th 2017 - Axxam is proud to announce its participation to the PHAGO project, an innovative research project devoted to the development of immunomodulatory therapies for Alzheimer’s disease (AD)....

read more

Axxam Celebrates 15th Anniversary

Axxam Celebrates 15th Anniversary Axxam is celebrating its 15th anniversary as a leading provider of integrated discovery services for the entire Life Sciences industry: "We are proud of having achieved this milestone through the passionate  work and dedication of our...

read more

Axxam executes a transaction with Acousia Therapeutics GmbH

Axxam executes a transaction with Acousia Therapeutics GmbH December, 14th 2016 – Axxam is proud to announce the closing of a transaction with Acousia Therapeutics GmbH, by which Axxam becomes a shareholder of Acousia and Dr. Stefan Lohmer, Chairman and Chief...

read more

Axxam SpA expands to U.S., opens office in Cambridge, Mass.

Axxam SpA expands to U.S., opens office in Cambridge, Mass. May 19th, 2016 - Axxam SpA (Milan/Italy), a privately owned innovative Partner Research Organization (iPRO) with a strong and leading expertise for the identification and characterization of bioactive...

read more

Drug Discovery Collaboration between Grünenthal and Axxam

Axxam SpA expands to U.S., opens office in Cambridge, Mass. Grünenthal capitalizes on Axxam’s drug discovery platform and expertise to identify small molecule lead structures for its early pipeline in pain and inflammation Aachen, Germany and Milano, Italy, March 3,...

read more